Strategy and Funding
The Sanger Institute uses genome sequences to advance understanding of the biology of humans and pathogens in order to improve human health.
Our scientific niche is in large-scale, high-throughput biology, often incorporating systematic genome-wide screens. These are enabled by major data generation platforms in DNA sequencing, cellular genetics and mouse genetics with an accompanying large IT platform supporting computational data analysis.
An overarching theme of our science is genome variation; naturally occurring and engineered, inherited and somatic; explored in human beings, pathogenic microorganisms, human cells and mice.
Our research is organised into Programmes:
- Cancer, Ageing and Somatic Mutation
- Cellular Genetics
- Human Genetics
- Parasites and Microbes
- Tree of Life
A major priority of our research portfolio is addressing scientific questions arising from the health issues facing low- and middle-income countries.
We dedicate resources to the organisation and presentation of data through publicly accessible databases and follow a policy of early and open data release.
The Institute positions itself at the centre of a network of science, engaging proactively with external researchers, enabling and empowering their science and extending our scientific repertoire through their biological insights and questions.
Genome Research Limited
The Institute and the wider Wellcome Genome Campus operate under the name of Genome Research Limited (GRL). GRL is a wholly owned subsidiary of the Wellcome Trust that facilitates the development of a long term and coherent strategy for the Campus and all activities on it. The ambition for GRL is to build on the Campus’ strong foundations to establish it as an international centre for scientific, business, cultural and educational activities emanating from Genomes and BioData by:
- advancing understanding of biology using genome sequences and biodata
- applying genome science for human health and other societal benefits
- fostering discussion of the scientific, medical and wider implications of genomes.
Please see, or download, the GRL Strategic Overview submission for 2021-2026:
The Sanger Institute is supported by a recurrent quinquennial core grant from the Wellcome Trust.
In addition to the core funding from the Wellcome Trust the Sanger Institute is also supported by a number of external grants from large and small funders including UK Research Councils, Charities, the EU and NIH.
Annual Financial Statements
Please download and read Genome Research Limited’s annual financial reports below.
Genome Research Limited Annual Report and Financial Statements for year ended 30 September
Download a PDF of the report, or view online:
Genome Research Limited Annual Report and Financial Statements - year ended 30 September 2019
Download the Report and Financial Statements for the year ended 30 September 2019
Find out more
Genome Research Limited Annual Report and Financial Statements - year ended 30 September 2018
Download the Report and Financial Statements for the year ended 30 September 2018
Find out more